|Drug class||Nonsteroidal antiandrogen|
|Chemical and physical data|
|Molar mass||394.892 g/mol g·mol−1|
|3D model (JSmol)|
Ralaniten (developmental code name EPI-002) is an N-terminal domain antiandrogen which was never marketed. It is a derivative of bisphenol A and one of the four stereoisomers of EPI-001. A prodrug of ralaniten, ralaniten acetate (EPI-506), was under development for the treatment of prostate cancer.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|